Sponsors
The bill aims to improve Medicare medication adherence and cut drug spending through AI/ML and greater use of generics/biosimilars—potentially improving health outcomes and lowering costs—but it raises privacy risks, possible limits on preferred brand therapies, and implementation and administrative costs.
Medicare beneficiaries with chronic conditions: AI/ML-enabled adherence efforts could raise medication adherence toward the 90% target, improving treatment effectiveness and reducing complications.
Patients and taxpayers: promoting greater use of generics and biosimilars could lower out-of-pocket drug costs for patients and reduce overall Medicare drug spending.
Hospitals and health systems: integrating AI/ML tools can enable targeted reminders and risk prediction to make adherence programs more efficient and better targeted.
Medicare beneficiaries and people with disabilities: using AI/ML and broader data-sharing for adherence tracking raises privacy and data‑security concerns.
Medicare beneficiaries reliant on specific brand therapies: aggressive promotion of generics/biosimilars may limit access to or discourage continued use of brand‑name drugs some patients need.
Hospitals, providers, and healthcare workers: implementing AI/ML adherence programs may impose administrative and technology costs and add operational burdens on health systems and staff.
Based on analysis of 2 sections of legislative text.
Requires HHS to set drug adherence guidelines aiming for 90% adherence for Medicare Part B and Part D drugs, using AI/ML and promoting generics and biosimilars.
Introduced February 7, 2025 by David Schweikert · Last progress February 7, 2025
Requires the Secretary of Health and Human Services to develop national drug adherence guidelines that aim for 90% adherence for all Medicare Part B and Part D drugs. The guidelines must incorporate artificial intelligence and machine learning tools and, to the maximum extent practicable, encourage use of generic and biosimilar medicines. The provision references existing Medicare definitions for Part B and Part D drugs. The text sets a target and technology expectations but does not specify funding, enforcement mechanisms, or detailed reporting requirements.